All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases

August 13th 2025

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

Dalpiciclib Plus Pyrotinib and Endocrine Therapy Displays Efficacy in ER+, HER2+ Advanced Breast Cancer

August 13th 2025

Dalpiciclib plus pyrotinib and endocrine therapy was active with a manageable safety profile in patients with ER-positive, HER2-positive advanced breast cancer.

Real-World Outcomes Support Use of First-Line Palbociclib Plus ET in HR+/HER2– Advanced Breast Cancer

August 12th 2025

Real-world data supported the clinical effectiveness of first-line palbociclib plus endocrine therapy in HR-positive, HER2-negative breast cancer.

Relacorilant Plus Nab-Paclitaxel May Serve As New Standard of Care in Platinum-Resistant Ovarian Cancer

August 12th 2025

Domenica Lorusso, MD, PhD, discusses the use of relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

Roswell Park Team Produces Genomics-Guided Tool to Inform Treatment of Advanced Kidney Cancers

August 12th 2025

Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies.

iPETcertum Receives FDA Clearance for Assisting in PET, PET-CT/MRI Scans for Patients With Cancer and Suspicious Lesions

August 12th 2025

The FDA has cleared iPETcertum for PET and PET-CT/MRI scan enhancement in patients with cancer and suspicious lesions.

Perioperative Enfortumab Vedotin Plus Pembrolizumab Displays Positive Top-Line Data in Muscle-Invasive Bladder Cancer

August 12th 2025

Perioperative enfortumab vedotin plus pembrolizumab significantly extended survival vs surgery alone in MIBC.

How Chemoimmunotherapy, PRRT, and First-Line Immunotherapy Are Reshaping GI Cancer Management

August 12th 2025

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

Daratumumab Delays Clinical Progression, Provides Proof-of-Concept for Early Intervention in MRD-Relapsed Multiple Myeloma

August 12th 2025

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

Expansion of BTK and BCL2 Inhibitors in CLL Requires Close Attention to Safety, Sequencing Considerations

August 12th 2025

Andrew Kuykendall, MD, discusses the evolving role of BTK inhibitors, as well as emerging targets and treatment modalities targeting BTK and BCL2 in CLL.

Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer

August 11th 2025

Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.

Ongoing Research Prompts Key Sequencing Considerations in CRC, Pancreatic Cancer

August 11th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma

August 11th 2025

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

Imsapepimut and Etimupepimut Plus Pembrolizumab Shows Clinical Improvement in PFS for Advanced Melanoma

August 11th 2025

The off-the-shelf therapeutic cancer vaccine plus pembrolizumab improved PFS vs pembrolizumab alone in advanced melanoma.

FDA Approves Oncomine Dx Target Test as Zongertinib Companion Diagnostic in Nonsquamous NSCLC With HER2 TKD Mutations

August 11th 2025

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic for zongertinib in NSCLC harboring HER2 TKD mutations.

Fulzerasib Displays Efficacy and Tolerability in KRAS G12C–Mutated Metastatic CRC

August 11th 2025

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

LV20.19 CAR T-Cell Therapy Yields 100% ORR in R/R Mantle Cell Lymphoma

August 11th 2025

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

Consensus on Clinical Trial End Points Is Essential for Improved Drug Development Across MPNs

August 11th 2025

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

Five Under 5: Top Oncology Videos for the Week of 8/3

August 10th 2025

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Breast Cancer

August 10th 2025

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.